The Week

Pfizer (PFE) slipped 0.39% this week to close at $27.96, underperforming the S&P 500, which rose 0.49%. The stock moved within a 2.88% range, with an early rally fading into the back half of the week. It opened Monday at $28.10 and closed at $27.97. Tuesday (Aug 25) saw the peak: an intraday high of $28.58 and a close of $28.57, the top of its 60-day range. Wednesday eased to $28.30, and Thursday and Friday both closed lower, ending the week at $27.96, almost back to where it started. Average daily volume was about 29.8m shares, roughly 23% below the 60-day median, pointing to a fairly quiet tape.

Key Events

The main company-specific development this week was the EMA accepting Pfizer’s Lyme disease vaccine application, which pushed the stock to a 52-week high on Tuesday. The news landed after market hours on Aug 25, and Pfizer outperformed its peers the following session. Separately, on Aug 28, the FDA approved updated COVID-19 vaccines for the 2026-27 season, with Moderna receiving similar clearance around the same time, marking a new round of vaccine updates at the industry level.

Several institutional position changes were disclosed: Korea Investment Corp sold shares, Westpac Banking Corp reduced its stake, Birmingham Capital Management opened a new position worth about $2.71m, and Redwood Investment Management bought 36,167 shares. EVP Cecile Guegan filed an initial beneficial ownership statement on Aug 29. Broader sector news included interim updates from RemeGen and Innovent, and reports of White House drug pricing deals with biotechs, though Pfizer-specific impact has not yet materialised.

Analyst Ratings

Pfizer is covered by 28 analysts: 8 rate it buy, 2 rate it overweight, 16 rate it hold, 1 rates it underweight and 1 rates it sell. The consensus recommendation is buy, with a consensus target of $28.60577, about 2.31% above the current price. The target range is wide: from $25.00 to $35.75, a gap of more than $10, reflecting divided views on how much upside remains. Within the pharmaceutical industry, Pfizer ranks 3rd out of 204 names, well above the industry mean of 6 and median of 5.

The Week Ahead

The coming week opens with a run of US macro data: Dallas Fed manufacturing activity on Aug 31 (prior 1.3), followed on Sep 1 by S&P Global manufacturing PMI final (prior 53.2), ISM manufacturing PMI (prior 55.6, forecast 55.2) and JOLTS job openings (prior 7.359m, forecast 7.3m). Sep 2 brings ADP private payrolls (prior 44, forecast 47), factory orders (prior -0.3%, forecast 0.6%) and weekly EIA crude inventories. Pfizer has no earnings on the calendar, but vaccine regulatory progress and any follow-up on the White House drug pricing talks are worth monitoring alongside sector news.

In Short

This week’s price action was event-driven rather than trend-led: the EMA’s acceptance of the Lyme disease vaccine application sparked a rally to a 52-week high, but most of that gain was given back over the next two sessions, leaving Pfizer slightly lower while the broader market rose. The analyst backdrop is supportive in aggregate — most brokers rate it buy or overweight, and the consensus target sits modestly above spot — but the wide target range signals real disagreement on the path from here. The latest day’s flow shows large-lot money as a net buyer while small-lot money was a net seller, with no consistent direction across order sizes. Valuation sits at about 36.8x earnings and 1.87x book, with a 6.15% dividend yield, consistent with the post-pandemic earnings reset. What matters next is the EMA review timeline for the Lyme vaccine, the rollout of newly approved COVID shots, and whether the macro calendar shifts risk appetite in the sector.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.